Report cover image

Global SARS-CoV-2 IgG (RBD) ELISA Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 199 Pages
SKU # APRC20360122

Description

Summary

According to APO Research, the global SARS-CoV-2 IgG (RBD) ELISA market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the SARS-CoV-2 IgG (RBD) ELISA market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for SARS-CoV-2 IgG (RBD) ELISA is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the SARS-CoV-2 IgG (RBD) ELISA market include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for SARS-CoV-2 IgG (RBD) ELISA, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of SARS-CoV-2 IgG (RBD) ELISA, also provides the value of main regions and countries. Of the upcoming market potential for SARS-CoV-2 IgG (RBD) ELISA, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the SARS-CoV-2 IgG (RBD) ELISA revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global SARS-CoV-2 IgG (RBD) ELISA market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global SARS-CoV-2 IgG (RBD) ELISA company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
SARS-CoV-2 IgG (RBD) ELISA Segment by Company

ALPCO
BD Biosciences
BioMérieux
Bio-Rad Laboratories
Enzo Life Sciences
LG
LOEWE Biochemica
Ortho Clinical Diagnostics
R&D Systems
Shenzhen YHLO Biotech
ZEUS Scientific
Thermo Fisher Scientific
SARS-CoV-2 IgG (RBD) ELISA Segment by Type

ELISA Sets
ELISA Kits
SARS-CoV-2 IgG (RBD) ELISA Segment by Application

Hospital
Clinic
Disease control and prevention system
SARS-CoV-2 IgG (RBD) ELISA Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global SARS-CoV-2 IgG (RBD) ELISA status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the SARS-CoV-2 IgG (RBD) ELISA key companies, revenue, market share, and recent developments.
3. To split the SARS-CoV-2 IgG (RBD) ELISA breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions SARS-CoV-2 IgG (RBD) ELISA market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify SARS-CoV-2 IgG (RBD) ELISA significant trends, drivers, influence factors in global and regions.
6. To analyze SARS-CoV-2 IgG (RBD) ELISA competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global SARS-CoV-2 IgG (RBD) ELISA industry.
Chapter 3: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of SARS-CoV-2 IgG (RBD) ELISA in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of SARS-CoV-2 IgG (RBD) ELISA in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global SARS-CoV-2 IgG (RBD) ELISA Market Size, 2020 VS 2024 VS 2031
1.3 Global SARS-CoV-2 IgG (RBD) ELISA Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 SARS-CoV-2 IgG (RBD) ELISA Market Dynamics
2.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
2.2 SARS-CoV-2 IgG (RBD) ELISA Industry Drivers
2.3 SARS-CoV-2 IgG (RBD) ELISA Industry Opportunities and Challenges
2.4 SARS-CoV-2 IgG (RBD) ELISA Industry Restraints
3 SARS-CoV-2 IgG (RBD) ELISA Market by Company
3.1 Global SARS-CoV-2 IgG (RBD) ELISA Company Revenue Ranking in 2024
3.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue by Company (2020-2025)
3.3 Global SARS-CoV-2 IgG (RBD) ELISA Company Ranking (2023-2025)
3.4 Global SARS-CoV-2 IgG (RBD) ELISA Company Manufacturing Base and Headquarters
3.5 Global SARS-CoV-2 IgG (RBD) ELISA Company Product Type and Application
3.6 Global SARS-CoV-2 IgG (RBD) ELISA Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 SARS-CoV-2 IgG (RBD) ELISA Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 SARS-CoV-2 IgG (RBD) ELISA Market by Type
4.1 SARS-CoV-2 IgG (RBD) ELISA Type Introduction
4.1.1 ELISA Sets
4.1.2 ELISA Kits
4.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type
4.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Type (2020-2031)
4.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type (2020-2031)
5 SARS-CoV-2 IgG (RBD) ELISA Market by Application
5.1 SARS-CoV-2 IgG (RBD) ELISA Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Disease control and prevention system
5.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application
5.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Application (2020-2031)
5.2.3 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application (2020-2031)
6 SARS-CoV-2 IgG (RBD) ELISA Regional Value Analysis
6.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2020-2031)
6.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region: 2020-2025
6.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2020-2031)
6.3.2 North America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value (2020-2031)
6.4.2 Europe SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value (2020-2031)
6.5.2 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America SARS-CoV-2 IgG (RBD) ELISA Sales Value (2020-2031)
6.6.2 South America SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value (2020-2031)
6.7.2 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Country, 2024 VS 2031
7 SARS-CoV-2 IgG (RBD) ELISA Country-level Value Analysis
7.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2020-2031)
7.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2020-2025)
7.2.2 Global SARS-CoV-2 IgG (RBD) ELISA Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.3.2 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.3.3 USA SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.4.2 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.5.2 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.6.2 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.7.2 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.7.3 France SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.8.2 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.9.2 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.10.2 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.11.2 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.14.2 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.14.3 China SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.15.2 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.16.2 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.17.2 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.17.3 India SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.18.2 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.20.2 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.21.2 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.22.2 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.23.2 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.24.2 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.26.2 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.27.2 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.28.2 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.29.2 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Growth Rate (2020-2031)
7.30.2 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt SARS-CoV-2 IgG (RBD) ELISA Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 ALPCO
8.1.1 ALPCO Comapny Information
8.1.2 ALPCO Business Overview
8.1.3 ALPCO SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.1.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.1.5 ALPCO Recent Developments
8.2 BD Biosciences
8.2.1 BD Biosciences Comapny Information
8.2.2 BD Biosciences Business Overview
8.2.3 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.2.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.2.5 BD Biosciences Recent Developments
8.3 BioMérieux
8.3.1 BioMérieux Comapny Information
8.3.2 BioMérieux Business Overview
8.3.3 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.3.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.3.5 BioMérieux Recent Developments
8.4 Bio-Rad Laboratories
8.4.1 Bio-Rad Laboratories Comapny Information
8.4.2 Bio-Rad Laboratories Business Overview
8.4.3 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.4.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.4.5 Bio-Rad Laboratories Recent Developments
8.5 Enzo Life Sciences
8.5.1 Enzo Life Sciences Comapny Information
8.5.2 Enzo Life Sciences Business Overview
8.5.3 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.5.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.5.5 Enzo Life Sciences Recent Developments
8.6 LG
8.6.1 LG Comapny Information
8.6.2 LG Business Overview
8.6.3 LG SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.6.4 LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.6.5 LG Recent Developments
8.7 LOEWE Biochemica
8.7.1 LOEWE Biochemica Comapny Information
8.7.2 LOEWE Biochemica Business Overview
8.7.3 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.7.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.7.5 LOEWE Biochemica Recent Developments
8.8 Ortho Clinical Diagnostics
8.8.1 Ortho Clinical Diagnostics Comapny Information
8.8.2 Ortho Clinical Diagnostics Business Overview
8.8.3 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.8.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.8.5 Ortho Clinical Diagnostics Recent Developments
8.9 R&D Systems
8.9.1 R&D Systems Comapny Information
8.9.2 R&D Systems Business Overview
8.9.3 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.9.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.9.5 R&D Systems Recent Developments
8.10 Shenzhen YHLO Biotech
8.10.1 Shenzhen YHLO Biotech Comapny Information
8.10.2 Shenzhen YHLO Biotech Business Overview
8.10.3 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.10.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.10.5 Shenzhen YHLO Biotech Recent Developments
8.11 ZEUS Scientific
8.11.1 ZEUS Scientific Comapny Information
8.11.2 ZEUS Scientific Business Overview
8.11.3 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.11.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.11.5 ZEUS Scientific Recent Developments
8.12 Thermo Fisher Scientific
8.12.1 Thermo Fisher Scientific Comapny Information
8.12.2 Thermo Fisher Scientific Business Overview
8.12.3 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Revenue and Gross Margin (2020-2025)
8.12.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
8.12.5 Thermo Fisher Scientific Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.